From the Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Sci Rep. 2017 Feb 22;7:43292. doi: 10.1038/srep43292.
There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH). A total of 149 patients who underwent detailed color Doppler ultrasound examination were included in this study. The characteristics and propranolol treatment of all patients were summarized and analyzed. Patients were divided into two groups according to the lesion regression rate. Among the 149 patients, 38 were assigned to the complete regression group, and 111 were assigned to the partial regression group. The age at which propranolol treatment started, duration of follow-up after treatment discontinuation and rate of adverse events were not significantly different between the two groups. The duration of oral propranolol treatment was shorter in the complete regression group. The age at which propranolol was terminated was younger in the complete regression group, and this group had a lower recurrence rate. Propranolol is safe and effective for the treatment of IHs that require intervention, but it should be stopped at an appropriate time, which is determined primarily by the lesion regression rate after propranolol treatment. Ultrasound is helpful in determining when to stop propranolol for IH.
关于婴儿血管瘤（IH）停止普萘洛尔治疗的最佳时机，尚无明确结论。本研究共纳入 149 例接受详细彩色多普勒超声检查的患者。总结分析了所有患者的特征和普萘洛尔治疗情况。根据病变消退率将患者分为两组。149 例患者中，完全消退组 38 例，部分消退组 111 例。两组患者普萘洛尔治疗起始年龄、停药后随访时间、不良反应发生率差异均无统计学意义。完全消退组患者口服普萘洛尔治疗时间较短。完全消退组普萘洛尔停药年龄较小，复发率较低。普萘洛尔治疗需要干预的 IH 安全有效，但应在适当的时间停药，主要由普萘洛尔治疗后病变消退率决定。超声有助于确定何时停止普萘洛尔治疗 IH。
